USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES
The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.
1 . A method of treating a progressive ovarian cancer in a subject in need thereof, comprising:
selecting a subject having had an initial treatment for the ovarian cancer; and
administering to the subject an effective amount of an immunogenic composition comprising an allogeneic leukemia-derived cell.
2 . (canceled)
3 . The method of claim 1 , wherein the administering is performed within about two weeks to about six months after the initial treatment for the ovarian cancer.
4 - 5 . (canceled)
6 . The method of claim 1 , wherein the administering is performed when the subject has exhibited an objective response following the initial treatment for the ovarian cancer.
7 . (canceled)
8 . The method of claim 1 , wherein the administering is performed when the subject suffers from recurrent cancer.
9 . (canceled)
10 . The method of claim 1 , wherein the allogeneic leukemia-derived cell expresses at least one tumor associated antigen selected from the group consisting of WT-1, MUC-1, RHAMM, PRAME, p53, and Survivin.
11 . (canceled)
12 . The method of claim 1 , wherein the allogeneic leukemia-derived cell comprises a dendritic cell phenotype.
13 . The method of claim 1 , wherein the allogeneic leukemia-derived cell comprises a mature dendritic cell phenotype.
14 - 15 . (canceled)
16 . The method of claim 1 , wherein the allogeneic leukemia-derived cell is CD34-positive, CD1a-positive, and CD83-positive.
17 . The method of claim 1 , wherein the allogeneic leukemia-derived cell expresses a cell surface marker selected from the group consisting of CD14, DC-SIGN, Langerin, CD80, CD86, CD70, CD40, and any combination thereof.
18 . The method of claim 1 , wherein the allogeneic leukemia-derived cell is derived from the DCOne cell line.
19 . The method of claim 1 , wherein the allogeneic leukemia-derived cell has been inactivated.
20 - 38 . (canceled)
39 . A method of treating a progressive ovarian cancer in a subject in need thereof, comprising:
administering to the subject an effective amount of an immunogenic composition comprising an allogeneic leukemia-derived cell.
40 - 46 . (canceled)
47 . The method of claim 39 , wherein the administering is performed when the subject suffers from recurrent cancer.
48 . (canceled)
49 . The method of claim 39 , wherein the allogeneic leukemia-derived cell expresses at least one tumor associated antigen selected from the group consisting of WT-1, MUC-1, RHAMM, PRAME, p53, and Survivin.
50 . (canceled)
51 . The method of claim 39 , wherein the allogeneic leukemia-derived cell comprises a dendritic cell phenotype.
52 . The method of claim 39 , wherein the allogeneic leukemia-derived cell comprises a mature dendritic cell phenotype.
53 - 54 . (canceled)
55 . The method of claim 39 , wherein the allogeneic leukemia-derived cell is CD34-positive, CD1a-positive, and CD83-positive.
56 . The method of claim 39 , wherein the allogeneic leukemia-derived cell expresses a cell surface marker selected from the group consisting of CD14, DC-SIGN, Langerin, CD80, CD86, CD70, CD40, and any combination thereof.
57 . The method of claim 39 , wherein the allogeneic leukemia-derived cell is derived from the DCOne cell line.
58 . The method of claim 39 , wherein the allogeneic leukemia-derived cell has been inactivated.
59 - 91 . (canceled)